Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Biomaterials. 2015 Mar 26;53:731–743. doi: 10.1016/j.biomaterials.2015.02.082

Figure 5. PLGA-ORM NPs inhibit p-AKT and the downstream key proteins associated with pancreatic carcinogenesis.

Figure 5

HPAF-II and BxPC-3 PanCa cells were treated with 20 µM ORM or PLGA-ORM 20 or their respective controls, for 48 h, and the cell lysates were collected and immunoblotted for p-Akt, PTEN, cyclin D1, p27, Bax, survivin, caspase-3, and β-actin (loading control). The results were consistent in two independent sets of experiments.